Pharmaceutical company
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9) 
Public Health Service Act (42 USC 6A); Drug safety: Food and Drug Administration Amendments Act of 2007 (Public Law No: 110-85); Food and Drug Import Safety Act (HR 3610); Drug reimportation: Pharmaceutical Market Access Act (S. 251); Pharmaceutical Market Access and Drug Safety Act (S. 242/HR 380). Follow-on biologics: Access to Life-Saving Medicine Act (HR 1038); Patient Protection and Innovative Biologic Medicines Act (HR 1956); Biologics Price Competition and Innovation Act (S. 1695); Pathway for Biosimilars Act (HR 5629).
Comparative Effectiveness: Comparative Effectiveness Research Act (S. 3408); Enhanced Health Care Value for All Act (HR 2184). General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement.
Physician gifts: Physician Payments Sunshine Act (S. 2029); Drug and Medical Device Company Gift Disclosure Act (HR 3023); False Claims Act Correction Act (HR 4854/S. 2041); Medicare Part D: Non-interference; Medicare Prescription Drugs and Modernization Act (Public Law 108-173); Medicare Prescription Price Negotiation Act (HR 4/S. 3). Medicare Improvements for Patients and Providers Act (HR 6331); Supplemental Appropriations Act (HR 2642).
HCR - Health Issues MMM - Medicare/Medicaid
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
CAPITOL HILL CONSULTING GROUP
926 Pennsylvania Ave, SE, Washington, DC, 20003, US
BILL K BREWSTER STEVEN E IRIZARRY BILL K BREWSTER STEVEN E IRIZARRY